Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer | Zendy

Peter Schmid | Zendy; Sylvia Adams | Zendy; Hope S. Rugo | Zendy; Andreas Schneeweiss | Zendy; Carlos H. Barrios | Zendy; Hiroji Iwata | Zendy; Véronique Dièras | Zendy; Roberto Hegg | Zendy; SeockAh Im | Zendy; Gail S. Wright | Zendy; Volkmar Henschel | Zendy; Luciana Molinero | Zendy; Jane Yuet Ching Hui | Zendy; Roel Funke | Zendy; Amreen Husain | Zendy; Eric P. Winer | Zendy; Sherene Loi | Zendy; Leisha A. Emens | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Author(s) -

Peter Schmid,

Sylvia Adams,

Hope S. Rugo,

Andreas Schneeweiss,

Carlos H. Barrios,

Hiroji Iwata,

Véronique Dièras,

Roberto Hegg,

SeockAh Im,

Gail S. Wright,

Volkmar Henschel,

Luciana Molinero,

Jane Yuet Ching Hui,

Roel Funke,

Amreen Husain,

Eric P. Winer,

Sherene Loi,

Leisha A. Emens

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1809615

Subject(s) - atezolizumab , triple negative breast cancer , paclitaxel , breast cancer , oncology , medicine , nab paclitaxel , hormone receptor , cancer , cancer research , immunotherapy , pembrolizumab

Unresectable locally advanced or metastatic triple-negative (hormone-receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)-paclitaxel may enhance the anticancer activity of atezolizumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research